<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion (IR) has been intensively investigated </plain></SENT>
<SENT sid="1" pm="."><plain>In general NO is regarded as a mediator of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-associated neuronal damage, as inhibitors of NO synthesis ameliorate neuronal injury during permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, however the exact role of NO in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> remains controversial </plain></SENT>
<SENT sid="2" pm="."><plain>It has been previously shown that NO-donors can directly inhibit the DNA binding activity of NF-kappaB family proteins and strong evidence supports that activation of NF-κB contributes to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced neuronal injury </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we have investigated whether NO production by nNOS, eNOS and iNOS modulates IkB-alpha expression in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, by using various inhibitors of NOS, in rats subjected to transient (1h) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAo) </plain></SENT>
<SENT sid="4" pm="."><plain>Male Wistar rats were treated intraperitoneally (i.p.) with 3mg/kg of NG-<z:chebi fb="13" ids="29785">nitro</z:chebi>-l-arginine <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (l-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, a non-selective NOS inhibitor), 5mg/kg of l-N6-(1-iminoethyl)-lysine (l-NIL, an inducible NOS inhibitor), 25mg/kg of 7-Nitroindazole (7-NI, a neuronal NOS inhibitor) and 10mg/Kg of l-N-(1-iminoethyl)<z:chebi fb="0" ids="18257">ornithine</z:chebi> (l-NIO, a selective eNOS inhibitor) 15min before the induction of tMCAo </plain></SENT>
<SENT sid="5" pm="."><plain>Cortical IkB-alpha expression was evaluated by western blotting and its decrease was considered as an indicator of NF-κB activation </plain></SENT>
<SENT sid="6" pm="."><plain>IkB-alpha expression decreased in ischemic cortices when compared with the cortices of the sham group, thus confirming the activation of NF-κB in ischemic conditions </plain></SENT>
<SENT sid="7" pm="."><plain>Pre-treatment with l-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, l-NIL and 7-NI significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and prevented <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced reduction in IkB-alpha expression </plain></SENT>
<SENT sid="8" pm="."><plain>Conversely, pretreatment with l-NIO was associated with a significant increase in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and a reduction in IkB-alpha expression </plain></SENT>
<SENT sid="9" pm="."><plain>These findings suggest that NO of neuronal and inducible origin promotes NF-κB activation via IkB-alpha modulation and mediates ischemic-related damage in the brain following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>